MannKind | MNKD - Sales Revenues


MannKind reported $109.37M in Sales Revenues for its fiscal quarter ending in June of 2026.





Sales Change Date
Adma Biologics USD 114.5M 24.66M Mar/2026
BioCryst Pharmaceuticals USD 218.25M 188.3M Jun/2026
Eli Lilly USD 24.4B 1.43B Sep/2026
Halozyme Therapeutics USD 481M 104M Jun/2026
Insmed USD 524.42M 98.93M Sep/2026
Karyopharm Therapeutics USD 35.07M 987K Mar/2026
MacroGenics USD 20.8M 20.43M Mar/2026
MannKind USD 109.37M 19.17M Jun/2026
Merck USD 18.1B 1.5B Sep/2026
Minerva Neurosciences USD 0 0 Sep/2024
Novavax USD 147.14M 76.69M Dec/2025
Novo Nordisk DKK 12.13B 84.69B Jun/2026
Pfizer USD 15.03B 530M Jun/2026
Sanofi EUR 11.95B 710M Jun/2026
Xencor USD 51.22M 46.71M Jun/2026